3rd Quarter - Amendment

PFIZER INC. for PFIZER INC.

Firm
Client
Income
—
Expenses
$3,420,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report Oct 20, 2011 $3,360,000 Replaced
3rd Quarter - Amendment (this page) May 25, 2012 $3,420,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Trans Pacific Partnership Negotiations Japan Market Access and Regulatory Issues US-Korea Free Trade Agreement Israel Patent Issues Brazil IP - WTO Case Australian FTA Implementation Chile IP Issues - FTA Implementation

LobbyistCovered position, as disclosed
KEN W COLE —
JOSEPH DAMOND —
ANGELA WALKER RIEMER —

Contacted: Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Food & Drug Administration (FDA); State, Dept of (DOS)

Taxation/Internal Revenue Code TAX

Repatriation Deferral Tax Extenders Excessive Returns Comprehensive Tax Reform Territorial Systems H.R. 2098, CFC Look Through Extension H.R. 1834, Freedom to Invest Act H.R. 2495, Tax Equity and Middle Class Fairness Act (excess returns) S. 1671, The Foreign Earnings Reinvestment Act S. 1346, the Stop Tax Haven Abuse Act

LobbyistCovered position, as disclosed
MARIA CINO —
KEN W COLE —
JENNIFER DUCK —
CAROLINE MOODY SCHELLHAS —

Contacted: Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP)

Bills named: S. 1346 (112th), H.R. 1834 (112th), H.R. 2098 (112th), H.R. 2495 (112th), S. 1671 (112th)

Copyright/Patent/Trademark CPT

Counterfeit Pharmaceuticals Patent Settlements Patent Reform Act, 2011 Protecting Consumer Access to Generic Drugs S. 27, Preserve Access to Affordable Generics S.23, America Invents Act, 2011 H.R. 1249, America Invents Act, 2011

LobbyistCovered position, as disclosed
JENNIFER DUCK —
JOHN PAUL HALLIWELL —
ANGELA WALKER RIEMER —
MARY BRIDGET WALSH —
JENNIFER SWENSON WALTON —

Contacted: State, Dept of (DOS); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Patent & Trademark Office (PTO)

Bills named: S. 23 (112th), H.R. 1249 (112th), S. 27 (112th)

Health Issues HCR

Health Care Reform Prescription Drug User Fee Act (PDUFA) Follow on Biologics Medicare Part D Antibiotic Incentives Tax Extenders Antimicrobial Resistance Homeland Security and Agriculture Appropriations Bill on Certified Importer Program Deficit Reduction/Joint Select Committee Issues (Budget Control Act) H.R. 965, The Preservation of Antibiotics for Medical Treatment Act, 2011 H.R. 979, FEHBP Priscription Drug Integrity, Transparency and Cost Savings Act, 2011 H.R. 452, Medicare Decisions Accountability Act S. 668, Health Care Bureacrats Elimination Act, 2011 S. 1094, Combating Autism Act S. 1599, FY 2012 Labor HHS Appropriations Bill

Contacted: Patent & Trademark Office (PTO); SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Food & Drug Administration (FDA); Executive Office of the President (EOP); Commerce, Dept of (DOC)

Bills named: H.R. 452 (112th), H.R. 979 (112th), S. 1094 (112th), S. 1599 (112th), H.R. 965 (112th), S. 668 (112th)

Medicare/Medicaid MMM

Medicare Prescription Drug Benefit Medicare Rebates/Medicare Part D Medicare Coverage Debt Ceiling and Part D Average Manufacturer Price Regulation Patient Protection and Affordable Care Act Implementation H.R. 452, Medicare Decision Accountability Act, 2011 S. 1206, Medicare Drug Savings Act

LobbyistCovered position, as disclosed
KEN W COLE —
JENNIFER DUCK —
JOHN PAUL HALLIWELL —
ANGELA WALKER RIEMER —
MARY BRIDGET WALSH —
JENNIFER SWENSON WALTON —

Contacted: Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); Patent & Trademark Office (PTO); SENATE; HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); State, Dept of (DOS); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Bills named: S. 1206 (112th), H.R. 452 (112th)

Consumer Issues/Safety/Products CSP

Importation Certified Importer Program Dextromethorphan Distribution Dextromethorphan Abuse Reduction The Food, Drug and Cosmetic Globalization Act ELDU Ban on Cephalosporin PSE Issues OTC Products in Flexible Spending Account Supply Chain Issues Counterfeits H.R. 741, Act to Prohibit the Marketing of Authorized Generic Drugs, 2011 S. 373, Fair Prescription Drug Competition Act, 2011

LobbyistCovered position, as disclosed
JENNIFER DUCK —
JOHN PAUL HALLIWELL —
MARY BRIDGET WALSH —
JENNIFER SWENSON WALTON —

Contacted: Commerce, Dept of (DOC); State, Dept of (DOS); SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); Executive Office of the President (EOP); Food & Drug Administration (FDA)

Bills named: H.R. 741 (112th), S. 373 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.